Clinical trial · Observational
Study Conducted Among Patients With CML
Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients With Chronic Myeloid Leukemia in Later Lines of Therapy
NCT05476562CI-TRIAL-00062060completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Retrospective, non-interventional observational cohort study conducted among patients with CML.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tyrosine Kinase Inhibitors (TKIs) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- First-line Therapy
- description
- A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
- interventionNames
- Other: Tyrosine Kinase Inhibitors (TKIs)
- label
- Second-line Therapy
- description
- A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
- interventionNames
- Other: Tyrosine Kinase Inhibitors (TKIs)
- label
- Third-line Therapy
- description
- A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: Patients were selected for the analysis of later lines of therapy in commercial claims (i.e., were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs) if they met the following criteria: * Had at least one diagnosis for CML, with first CML diagnosis observed in claims on or after May 10, 2001, the date of FDA approval for imatinib * Were at least 18 years of age as of the first CML diagnosis * Started a first line therapy for CML with imatinib, dasatinib, nilotinib, or bosutinib (conditional on FDA-approval dates) * Initiated first line therapy within a maximum of 1 month prior to the first diagnosis for CML or a maximum 3 months following the first diagnosis for CML * Had continuous health plan enrollment (pharmacy and medical benefits) from the washout period to at least 12 months following the first CML diagnosis Exclusion Criteria: * Patients had a diagnosis for CML remission or relapse anytime prior to first line therapy * Patients had a medical claim associated with a clinical trial during the washout period up to the end of the observation period * Patients had an HSCT during the washout period up to the first line therapy initiation * Patients had chemotherapy treatment (except hydroxyurea) during the washout period up to the first line therapy initiation
References
Publications (0)
Data not yet available
No reference posted for this study.